India, Mumbai, June 17, 2016: National Immunobiological Company (State Corporation
Rostech) together with Cipla Limited, a global pharmaceutical company, during SPIEF'16
signed Memorandum of Understanding on innovative antiviral medical products for HIV and
Hepatitis C treatment and on technology transfer and active pharmaceutical ingredients (API)
manufacturing. New drugs production will help to change therapeutic regimens and
substantially increase availability of drugs for Russian patients. By 2019 total market share for
anti-HIV drugs will increase to 60%.
Nacimbio CEO Nikolay Semenov and Chandru Chawla, Head of Cipla New Ventures, signed the Memorandum of Understanding on technology transfer for manufacturing of anti-HIV drugs and drugs for Hepatitis C treatment.
“Today patients undergoing anti-HIV treatment have to take a lot of drugs every day. Our preparations will meet the expectations of Russian patients and will solve this problem. In 2017 we will finalize construction and validation of the manufacturing plant together with Cipla Ltd., products will be commercially available in 2018. Total investment in the project will be over 2.8 billion roubles, stated Nacimbio CEO Nikolay Semenov.”
“Currently there is no technology for full-cycle manufacturing of HIV treatment drugs in Russia,” said Subhanu Saxena, MD & Global CEO, Cipla Ltd. “We are glad that, as a responsible partner together with Nacimbio we will be able to improve drug availability for patients and make our contribution to the fight against HIV.”
About Cipla Limited
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.
Cipla's research and development focuses on developing innovative products and drug delivery systems.
Cipla Media Contacts:
Corporate Communications
Charlotte Chunawala
Mobile: +91 7506257377
E Mail: charlotte.chunawala@cipla.com;
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com
Nacimbio CEO Nikolay Semenov and Chandru Chawla, Head of Cipla New Ventures, signed the Memorandum of Understanding on technology transfer for manufacturing of anti-HIV drugs and drugs for Hepatitis C treatment.
“Today patients undergoing anti-HIV treatment have to take a lot of drugs every day. Our preparations will meet the expectations of Russian patients and will solve this problem. In 2017 we will finalize construction and validation of the manufacturing plant together with Cipla Ltd., products will be commercially available in 2018. Total investment in the project will be over 2.8 billion roubles, stated Nacimbio CEO Nikolay Semenov.”
“Currently there is no technology for full-cycle manufacturing of HIV treatment drugs in Russia,” said Subhanu Saxena, MD & Global CEO, Cipla Ltd. “We are glad that, as a responsible partner together with Nacimbio we will be able to improve drug availability for patients and make our contribution to the fight against HIV.”
About Cipla Limited
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.
Cipla's research and development focuses on developing innovative products and drug delivery systems.
Cipla Media Contacts:
Corporate Communications
Charlotte Chunawala
Mobile: +91 7506257377
E Mail: charlotte.chunawala@cipla.com;
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com
